Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says
Company says it is in active licensing discussions with “probably half a dozen” firms.
Company says it is in active licensing discussions with “probably half a dozen” firms.